Key result
Androgen deprivation and AR pathway inhibitors substantially raise cardiometabolic risk in prostate cancer patients.
Prostate cancer treatments, particularly androgen deprivation therapy and androgen receptor pathway inhibitors, significantly increase cardiovascular risk, necessitating proactive cardiovascular risk factor management in this population.
Supports integrated cardio-oncology evaluation in prostate cancer; leaves open optimal risk-mitigation strategies for prospective trials.
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.
No takes yet. Share an insight, caveat, or question.
Leong et al. (2024) conducted a review in Prostate Cancer and Cardiovascular Disease. Prostate cancer treatments (Androgen Deprivation Therapy and Androgen Receptor Pathway Inhibitors) was evaluated. Cardiovascular disease is a leading cause of death in prostate cancer patients, and treatments like androgen deprivation therapy and androgen receptor pathway inhibitors further increase the risk of cardiometabolic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: